New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Os...( HONOLULU Sept. 19 /- Results from...),Health
| HOME >> MEDICINE >> TECHNOLOGY |
HONOLULU, Sept. 19 /PRNewswire-FirstCall/ -- Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were presented at the American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting. In the non-inferiority study comparing risedronate 150 mg once monthly to risedronate 5 mg daily [Actonel(R) (risedronate sodium tablets)] increases in bone mineral density (BMD) were similar for patients taking either the monthly or daily dosing regimens.
In the study, BMD was measured at the lumbar spine, total hip, femoral neck, and femoral trochanter. There were no statistically significant differences in BMD increases between the risedronate 150 mg once monthly and the 5 mg daily dose groups at 12 months. In the study, the tolerability and safety profiles were also similar for the monthly and daily dosing regimens of risedronate.
"Risedronate is already approved to reduce the risk of both spinal and nonspinal fractures," said Michael McClung, M.D., Founding Director of the Oregon Osteoporosis Center in Portland, Oregon. "For patients who prefer less frequent dosing, risedronate 150 mg, if approved, would provide the convenience of a once monthly dosing option."
About the Study
The MERIT-OP (Monthly Evaluation of Risedronate Trial in Osteoporosis)
study is a 2-year, randomized, double-blind, active-control (5 mg daily
risedronate) clinical trial which evaluated 1,292 postmenopausal women (94%
Caucasian) between 50 and 88 years old, mean age 64.9, from 47 clinical
centers in 13 countries. The participants had osteoporosis, defined as a
lumbar spine (LS) BMD T-score less than -2.5 or a LS BMD T-score less than
- 2.0 and at least one prevalent vertebral fracture. Patients were
randomized to dosing regimens of either risedronate 150 mg monthly or
risedronate 5 mg daily and received daily supplements of calcium (1,000 mg)
and vitamin D (400
'/>"/>
| SOURCE The Alliance for Better Bone Health Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |